27.30
price down icon2.53%   -0.71
after-market アフターアワーズ: 27.48 0.18 +0.66%
loading
前日終値:
$28.01
開ける:
$27.96
24時間の取引高:
2.32M
Relative Volume:
1.44
時価総額:
$2.58B
収益:
$522.75M
当期純損益:
$-558.99M
株価収益率:
-4.2195
EPS:
-6.47
ネットキャッシュフロー:
$-439.53M
1週間 パフォーマンス:
-0.40%
1か月 パフォーマンス:
-26.53%
6か月 パフォーマンス:
-38.02%
1年 パフォーマンス:
-39.48%
1日の値動き範囲:
Value
$27.11
$28.21
1週間の範囲:
Value
$25.81
$28.52
52週間の値動き範囲:
Value
$25.81
$60.37

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Name
名前
Ultragenyx Pharmaceutical Inc
Name
セクター
Healthcare (1162)
Name
電話
415-483-8800
Name
住所
60 LEVERONI COURT, NOVATO, CA
Name
職員
1,294
Name
Twitter
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
RARE's Discussions on Twitter

RARE を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RARE
Ultragenyx Pharmaceutical Inc
27.30 2.50B 522.75M -558.99M -439.53M -6.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-05-28 開始されました William Blair Outperform
2024-06-06 アップグレード Goldman Neutral → Buy
2024-04-22 開始されました RBC Capital Mkts Outperform
2023-12-08 開始されました Wells Fargo Overweight
2023-06-14 再開されました Credit Suisse Outperform
2023-06-06 アップグレード Evercore ISI In-line → Outperform
2023-04-26 開始されました Cantor Fitzgerald Overweight
2023-01-18 再開されました Canaccord Genuity Buy
2022-12-30 再開されました H.C. Wainwright Buy
2022-11-03 アップグレード Robert W. Baird Neutral → Outperform
2022-10-13 アップグレード Guggenheim Neutral → Buy
2022-08-01 ダウングレード Evercore ISI Outperform → In-line
2022-03-16 アップグレード Credit Suisse Neutral → Outperform
2022-02-11 アップグレード JP Morgan Neutral → Overweight
2021-09-30 開始されました H.C. Wainwright Buy
2021-08-19 開始されました UBS Sell
2021-07-15 開始されました Guggenheim Neutral
2021-06-29 アップグレード BofA Securities Neutral → Buy
2021-06-04 再開されました Robert W. Baird Neutral
2021-05-06 アップグレード Citigroup Neutral → Buy
2021-05-06 アップグレード Evercore ISI In-line → Outperform
2021-04-26 再開されました Credit Suisse Neutral
2021-03-02 再開されました Stifel Buy
2021-02-12 ダウングレード JP Morgan Overweight → Neutral
2020-12-07 ダウングレード Wedbush Outperform → Neutral
2020-11-24 再開されました Evercore ISI In-line
2020-11-12 ダウングレード BofA Securities Buy → Neutral
2019-08-02 再開されました Wedbush Outperform
2019-03-27 アップグレード Morgan Stanley Equal-Weight → Overweight
2019-02-22 再開されました Raymond James Outperform
2019-01-02 ダウングレード Raymond James Outperform → Mkt Perform
2018-11-08 アップグレード Citigroup Sell → Neutral
2018-09-10 開始されました Morgan Stanley Equal-Weight
2018-06-21 ダウングレード Credit Suisse Outperform → Neutral
2018-05-11 アップグレード Barclays Equal Weight → Overweight
2018-05-10 開始されました Goldman Neutral
2018-04-18 アップグレード SunTrust Hold → Buy
2018-03-22 再開されました Piper Jaffray Overweight
2018-02-21 繰り返されました Stifel Buy
2018-01-22 アップグレード Evercore ISI In-line → Outperform
2018-01-18 開始されました Credit Suisse Outperform
2017-12-05 繰り返されました Barclays Equal Weight
2017-12-04 アップグレード Jefferies Hold → Buy
2017-09-14 アップグレード Wedbush Neutral → Outperform
すべてを表示

Ultragenyx Pharmaceutical Inc (RARE) 最新ニュース

pulisher
Jul 23, 2025

Ultragenyx Pharmaceutical Inc. Stock Analysis and ForecastSkyrocketing profit margins - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Ultragenyx Pharmaceutical Inc. stock priceRapid portfolio appreciation - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.

Jul 23, 2025
pulisher
Jul 22, 2025

RARE ACTIVE INVESTIGATION: Lost Money on Ultragenyx Pharmaceutical Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Ultragenyx Pharmaceutical Inc. stockUnmatched profit potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Ultragenyx Pharmaceutical (RARE) Gets a Complete Response Letter for UX111 - Insider Monkey

Jul 22, 2025
pulisher
Jul 22, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - PR Newswire

Jul 22, 2025
pulisher
Jul 22, 2025

Is Ultragenyx Pharmaceutical Inc. a good long term investmentConsistently high returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Lost Money on Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire

Jul 21, 2025
pulisher
Jul 21, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ultragenyx Pharmaceutical Inc. (RARE) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Jul 21, 2025
pulisher
Jul 21, 2025

Lost Money on Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire

Jul 21, 2025
pulisher
Jul 20, 2025

11 Best All-Time Low Stocks to Buy According to Analysts - Insider Monkey

Jul 20, 2025
pulisher
Jul 20, 2025

William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE) - MSN

Jul 20, 2025
pulisher
Jul 20, 2025

Ultragenyx Grants Restricted Stock Units to New Employees, Expands Workforce and Focus on Rare Diseases. - AInvest

Jul 20, 2025
pulisher
Jul 20, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Investors to Inquire about Securities Investigation - ACCESS Newswire

Jul 20, 2025
pulisher
Jul 20, 2025

Did You Suffer Losses in Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire

Jul 20, 2025
pulisher
Jul 18, 2025

Shareholders Alert: Investigation Into Ultragenyx Pharmaceutical Inc. (RARE)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire

Jul 18, 2025
pulisher
Jul 18, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 18, 2025
pulisher
Jul 18, 2025

Rare Disease Leader Ultragenyx Expands Team with 45,292 Stock Grants to New Hires - Stock Titan

Jul 18, 2025
pulisher
Jul 18, 2025

RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm - The Globe and Mail

Jul 18, 2025
pulisher
Jul 18, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Investors to Reach Out - ACCESS Newswire

Jul 18, 2025
pulisher
Jul 18, 2025

Ultragenyx stock hits 52-week low at $26.85 By Investing.com - Investing.com Canada

Jul 18, 2025
pulisher
Jul 18, 2025

Published on: 2025-07-18 04:31:12 - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

Why Ultragenyx Pharmaceutical Inc. stock is on top investor watchlistsDouble Your Capital Alerts - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal trials By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal trials - Investing.com

Jul 17, 2025
pulisher
Jul 17, 2025

Sarepta Therapeutics Announces Workforce Reductions as FDA Rejects Ultragenyx Rare Disease Drug Over Manufacturing Concerns - geneonline.com

Jul 17, 2025
pulisher
Jul 17, 2025

Ongoing Securities Investigation into Ultragenyx Pharmaceutical Inc. (RARE)Contact Levi & Korsinsky - ACCESS Newswire

Jul 17, 2025
pulisher
Jul 17, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Stockholders to Reach Out - ACCESS Newswire

Jul 17, 2025
pulisher
Jul 17, 2025

Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE) - Insider Monkey

Jul 17, 2025
pulisher
Jul 17, 2025

Hutchinson-Gilford Progeria Syndrome Market Driven - openPR.com

Jul 17, 2025
pulisher
Jul 17, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Stockholders to Connect - ACCESS Newswire

Jul 17, 2025
pulisher
Jul 16, 2025

Ultragenyx, Mereo in selloff after trial update on bone disorder therapy - MSN

Jul 16, 2025
pulisher
Jul 16, 2025

Why Ultragenyx Pharmaceutical Inc. stock attracts strong analyst attentionMinimized Risk Trading Plan - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder - MSN

Jul 15, 2025
pulisher
Jul 15, 2025

Ultragenyx gets Complete Response Letter for Sanfilippo syndrome gene therapy - MSN

Jul 15, 2025

Ultragenyx Pharmaceutical Inc (RARE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
大文字化:     |  ボリューム (24 時間):